Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.61 |
| ▸ | PNP | P00491 | 6/20 | 0.57 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857473 | 0.90 | XDH (0.60) | XDHPNPMEN1KMT2AUSP2 | |
| SCHEMBL9705489 | 0.84 | XDH (0.42) | XDHPNP | |
| SCHEMBL3774142 | 0.80 | TK1 (0.41) | XDHPNPTK1 | |
| SCHEMBL13012219 | 0.79 | TYMP (0.45) | XDHMEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL5021598 | 0.79 | XDH (0.55) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL21417341 | 0.77 | XDH (0.53) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL1286945 | 0.76 | XDH (1.00) | XDHPNPTK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL21799342 | 0.75 | XDH (0.97) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL5694190 | 0.75 | XDH (0.60) | XDHPNPTK1USP2TSHR | |
| SCHEMBL21539869 | 0.74 | XDH (0.50) | XDHPNPTK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | claimed |
| US-6825348-B2 | Antiviral compounds | ACADEMIA SINICA (TW) | 2004-11-30 | — | — | US | disclosed |
| US-20040002475-A1 | Dna genome | ACADEMIA SINICA (TW) | 2004-01-01 | — | — | US | disclosed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002475-A1 | Dna genome | DNA2, OGG1, UNG | XDH 65/4885PNP 36/4885TK1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.